People · Operator
Named in public records as an officer, director or promoter · active 2009–2021 · Healthtech, Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Hinge Health, Inc. | — | Healthtech | Series D+ | $862.5M | $7.7B | 2016 |
| Presidio Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $72.6M | $742.2M | 2009 |
| Hyperion Therapeutics Inc | — | Pharmaceuticals | Series B | $67.9M | $271.7M | 2009 |
| Statera Biopharma, Inc. | — | Biotechnology | Series B | $35.5M | $8.4M | 2009 |
| Accelerated Pharma, Inc. | — | Pharmaceuticals | Seed | $3.5M | $9.5M | 2016 |
Daniel Perez at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel Perez on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Fonstein | 2 | 3 |
| Teddie Wardi | 1 | 10 |
| Srinivas Akkaraju | 1 | 10 |
| David Wood | 1 | 8 |
| Peter Segall | 1 | 8 |
| James Healy | 1 | 8 |
| James I. Healy | 1 | 7 |
| Kenneth Galbraith | 1 | 6 |
| Steve Kraus | 1 | 6 |
| Ben Blume | 1 | 6 |
| Rob Hopfner | 1 | 6 |
| Bijan Salehizadeh | 1 | 5 |
| Jake Nunn | 1 | 5 |
| Robert Williamson | 1 | 5 |
| Jake R. Nunn | 1 | 4 |
| Elliott Robinson | 1 | 4 |
| Lota S Zoth | 1 | 4 |
| Donald Santel | 1 | 4 |
| Felix Baker | 1 | 4 |
| Robert Hopfner | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.